It has been almost a year since we announced that AMBRoSIA (AMulticentre Biomarker Resource Strategy In ALS) had begun to recruit participants (read the Autumn 2017 edition of Thumbprint).
AMBRoSIA is the biggest project that the MND Association has ever funded and recruitment occurs at three sites throughout the UK (Sheffield, headed by Prof Dame Pam Shaw, Oxford, headed by Prof Martin Turner and London, headed by Dr Andrea Malaspina).
The project will collect a number of biological samples, including blood, cerebrospinal fluid (CSF), urine and skin in order to identify biomarkers (markers of biological change) that could be a signature of MND.Read More »
Janine Kirby is a Non-Clinical Reader in Neurogenetics and is celebrating 20 years in motor neurone disease (MND) research this month. Here she tells us more about how she got into the field, her current projects, what it’s like to work at Sheffield Institute for Translational Neuroscience (SITraN) and to meet families affected by MND.
How and why did you get into MND research?
Having completed my PhD at University College London, I wanted to apply my knowledge of genetics to medical research. I subsequently joined the MND Research Group at the University of Newcastle-upon-Tyne, headed by Prof Pamela Shaw, looking at the frequency of genetic changes in the SOD1 gene in MND patients from the North East of England.
Since then, firstly at Newcastle and then at the University of Sheffield, I have provided genetic input to the research strategy of investigating the molecular basis of this complex genetic disorder. I am now a Reader in Neurogenetics at SITraN working not only on the genetics of MND but also using a method termed transcriptomics (basically which genes are being switched on or off, and by how much) to discover biomarkers for the disease and to understand why the motor neurones are dying.
20 years later I’m still here because it’s incredibly challenging and interesting research, with the opportunity to work with great colleagues and collaborators across the world.Read More »
The day finally arrived on 11 April 2014 for our biannual Biomedical Research Advisory Panel (BRAP) Meeting. This important date in our research calendar is when grant funding decisions are discussed before being put forward to our Board of Trustees for approval.
But before we get to the meeting, there is a lot of preparation that is needed. As you are aware from previous blog posts, applications go through various stages of review, including summary review, invites for full applications and external review. Before the meeting itself there is yet another stage of review for the applications, which is known as internal review. This might seem a bit ‘admin-heavy’, but since we are only able to fund a quarter of such a wide variety of proposals, ranging from cell-based studies to clinical research, we need to be confident that we’re funding the ‘best of the best’. With so many new ideas, ‘separating the wheat from the chaff’ can be a difficult and time-consuming process!
The 24th International Symposium on ALS/MND is now only one week away! We’re busy making final preparations and getting ready to report from the event, whilst researchers around the world are packing their suitcases, finishing off their posters and tweaking their presentations.
But, what is it like to attend the symposium? What do researchers gain from attending? One of our grantees, and member of our Biomedical Research Advisory Panel (BRAP), Dr Janine Kirby (Sheffield Institute for Translational Neuroscience) will be attending this year’s event. Dr Kirby has kindly agreed to explain why she attends the symposium and what researchers gain by attending this prestigious event:
“The symposium gives you the opportunity to surround yourself with the latest motor neurone disease research from across the world in one location. From advances in genetics to the latest healthcare research the symposium really does have it all!